NCT04163419View on ClinicalTrials.gov

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2024

Conditions

SchwannomatosisPain

Interventions

DRUG

Tanezumab

Tanezumab 10 mg SC

DRUG

Placebo

Placebo 10 mg SC

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Massachusetts General Hospital

OTHER